AstraZeneca Pharma India to launch Enhertu in January 2024
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
ABDM Microsites Mobile Application for field officers and ABDM Microsites Dashboard launched for effective on-ground implementation and monitoring
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
10+ emerging markets, Japan & ANZ transition in final phase
Expands patient reach to remotest towns by furthering investment in GoApptiv
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
The product will be manufactured at Lupin's Pithampur facility in India
Subscribe To Our Newsletter & Stay Updated